Loading...
Loading...
KRON| Name | Value |
|---|---|
| Revenues | 0.9M |
| Cost of Revenue | 0.5M |
| Gross Profit | 0.4M |
| Operating Expense | 34.7M |
| Operating I/L | -33.8M |
| Other Income/Expense | 2.5M |
| Interest Income | 2.5M |
| Pretax | -31.4M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -31.4M |
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative cancer therapeutics. The company's product engine targets dysregulated transcription factors and the transcriptional regulatory networks driving oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. Kronos Bio also focuses on developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, currently in phase 1/2 clinical trial.
